ACCESS Newswire

Luvu Brands, Inc.

Share
Luvu Brands Provides Preliminary Q4 and Fiscal Year Net Sales

Preliminary fiscal 2021 net sales are 25% ahead of prior fiscal year

ATLANTA, GA / ACCESSWIRE / July 15, 2021 / Luvu Brands, Inc., (OTCQB:LUVU), a designer, manufacturer and marketer of a portfolio of consumer lifestyle brands, today announced that preliminary unaudited net sales for the three months ended June 30, 2021 were approximately $5.9 million (or approximately 7% higher) than the $5.5 million recorded in the same period of 2020. Included in the prior year three months ended June 30, 2020 results were $780,000 in sales of PPE products. Excluding the non-recurring PPE sales, the comparable quarter-to-quarter increase was approximately 25%. For the twelve months ended June 30, 2021, preliminary net sales were a record $23.1 million, an increase of approximately 25% from the $18.4 million reported for the prior fiscal year.

Note About Preliminary Results
The estimated preliminary net sales for the fourth quarter and twelve months ended June 30, 2021, presented in this release are not reviewed or audited and may change. The preliminary unaudited net sales presented herein include calculations or figures that have been prepared internally by management and have not been reviewed by our independent registered public accounting firm. There can be no assurances that Luvu Brands reported net sales for the fourth quarter and twelve months ended June 30, 2021, will not differ from the amounts presented herein. This preliminary financial data should not be viewed as a substitute for full audited financial statements prepared in accordance with GAAP and is not necessarily indicative of the results to be achieved for any future period. Our audited financial statements for the three and twelve months ended June 30, 2021, will be contained in our Annual Report on Form 10-K to be filed with the Securities and Exchange Commission.

Forward-Looking Statements
This press release contains forward-looking statements. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. Luvu Brands has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements are unknown at this time. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, including, but not limited our ability to, statements regarding our preliminary unaudited net sales information presented herein, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You are urged to carefully review any cautionary statements and other disclosures in Luvu Brand's Annual Report on Form 10-K for the year ended June 30, 2020, and its other filings with the Securities and Exchange Commission. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Luvu Brands undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

About Luvu Brands
Luvu Brands, Inc. designs, manufactures and markets a portfolio of consumer lifestyle brands through the Company's websites, online mass merchants and specialty retail stores worldwide. Brands include: Liberator®, a brand category of iconic products for enhancing sexual performance; Avana®, inclined bed therapy products, assistive in relieving medical conditions associated with acid reflux, surgery recovery and chronic pain; and Jaxx®, a diverse range of casual fashion daybeds, sofas and beanbags made from polyurethane foam and repurposed polyurethane foam trim. Headquartered in Atlanta, Georgia, the Company occupies a 140,000 square foot vertically integrated manufacturing facility and employs over 200 people. The Company's brand sites include: www.liberator.com, www.jaxxliving.com, www.avanacomfort.com plus other global e-commerce sites. For more information about Luvu Brands, please visit www.luvubrands.com.

Company Contact:
Luvu Brands, Inc.
Ronald Scott
Chief Financial Officer
770-246-6426
ron@LuvuBrands.com

SOURCE: Luvu Brands, Inc.



View source version on accesswire.com:
https://www.accesswire.com/655588/Luvu-Brands-Provides-Preliminary-Q4-and-Fiscal-Year-Net-Sales

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Karbon-X Advances Community-Led Forest Protection in Colombia's Meta Region19.11.2025 15:00:00 CET | Press release

New phase of the Sur del Meta Project expands carbon and biodiversity monitoring while strengthening local governance and livelihoods. CALGARY, AB / ACCESS Newswire / November 19, 2025 / In the heart of Colombia's Meta department, where forests and farmlands converge, Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is deepening its commitment to people-powered climate solutions through the REDD+ Sur del Meta Project - a long-term conservation initiative that protects 40,637 hectares of natural forest while supporting sustainable livelihoods for nearly 1,000 local families. Developed through ALLCOT - A Karbon-X Company, the project development and advisory arm of Karbon-X, the initiative operates across the municipalities of Vistahermosa, Puerto Rico, Puerto Concordia, and Puerto Lleras, a region historically affected by deforestation and armed conflict. The project partners with local farmers, many of whom are victims of Colombia's armed conflict, helping them transition from

eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release

MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye

IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release

Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres

General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release

DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG

OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release

OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye